![]() ![]() Jason Nasser, MD is a resident physician in Internal Medicine from Cleveland Clinic in Ohio and a member of the ABC News Medical Unit.Action Movie FX is a relatively new mobile app that allows you to add cinema-grade special effects to your own footage. He added, “I would encourage patients to join those trials because that is the best way to find out…whether drugs work or not, and whether tests work or not.” “The findings of this study are provocative, but not sufficient to just yet change clinical practice,” Khorana said, “although I foresee that that's going to happen very, very soon in the near future.” This study shows that there is also benefit for stage III and stage IV cancers. MORE: Kirstie Alley's death at 71 puts spotlight on colon cancer: What women need to knowĪ June 2022 trial published in the New England Journal of Medicine also showed that ctDNA can be safely used to guide chemotherapy decisions in stage II colon cancer. “The impact of this individual paper should be taken into the context of other papers that have recently come out and are ongoing…It has a meaningful impact in allowing us to not only identify high-risk patients, but also showing that giving them chemotherapy after the surgery is beneficial,” said Khorana. Still, experts said, more research is needed before this test becomes a standard part of medical care. “Even though we've been relying on those for many decades, all of those were far, far less predictive of who was going to have their cancer return,” Kamath said. But this new study suggests the blood test would be more accurate, Kamath said. We use a lot of other factors, like how progressive the tumor is and how many lymph nodes are involved.”Ĭurrently, oncologists use other clues - such as the characteristics of the tumor itself - to help them gauge which patients need additional chemotherapy. ![]() “What's interesting too was that was by far the strongest factor. Suneel Kamath, a gastrointestinal oncologist at the Cleveland Clinic, who was also not involved with the study. “What the study showed was that the people who had the liquid biopsy, or ctDNA, being positive after surgery, had an extremely, extremely high chance of recurrence…10 times higher risk compared to people who were ctDNA negative,” said Dr. MORE: With young people getting colon cancer at high rates, doctors highlight importance of screening This study showed that patients with positive tests likely need additional chemotherapy, whereas those with negative tests might be able to safely skip the taxing and toxic treatment. A positive test suggests there are still residual cancer cells in the body. In the recently published study, researchers looked for the presence of this genetic material in more than 1,000 patients who had undergone surgery to remove stage II, III, and IV colon cancer. The blood test, made by genetic testing and diagnostic company Natera, is also sometimes called a “liquid biopsy.” It detects small fragments of genetic material called circulating tumor DNA (or ctDNA), which are shed by the cancer into the blood stream. Worldwide, it's also very common and is rising in many countries where in the past, it was not that common.” “Colorectal cancer is one of the most common cancers in the country, affecting both men and women. Alok Khorana, director of the gastrointestinal malignancies program at the Cleveland Clinic, who was not involved with the study. ![]() “Potentially, worldwide, we're talking about millions of people,” said Dr. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |